Author

Lucia Mendo

Observed name: L. Mendo

Institutions: Ospedale San Bortolo, Azienda ULSS 8 Berica

Observed institutions: University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Ospedale San Bortolo, Azienda ULSS 8 Berica

ORCID: 0009-0009-1041-151X

Observed ORCID: 0009-0009-1041-151X

OpenAlex ID: A5099013112

Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).

2024 · Davide Melisi, Alberto Quinzii, et al. · Journal of Clinical Oncology · 5

304P Clinical response to futibatinib in intrahepatic cholangiocarcinoma with acquired resistance to fibroblast growth factor receptor 2 inhibitors

2024 · S. Casalino, C. Gerdes, et al. · Annals of Oncology · 2

Futibatinib after non-covalent FGFR inhibitors in FGFR2-rearranged intrahepatic cholangiocarcinoma: clinical activity and resistance patterns

2026 · Simona Casalino, Enza Scarlato, et al. · European Journal of Cancer

Early-onset enriches the identification of actionable alterations in patients with KRAS wild-type pancreatic ductal adenocarcinoma

2025 · E. Scarlato, S. Casalino, et al. · ESMO Gastrointestinal Oncology

107P Early-onset enriches the identification of actionable alterations in patients with KRAS wild-type pancreatic ductal adenocarcinoma

2025 · E. Scarlato, S. Casalino, et al. · ESMO Open

Works count: 5

Citation count: 7

H-index: 2

I10-index: